Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation

Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation

The purpose of this study is to characterize changes in the plasma proteome over time following left ventricular assist device (LVAD) implantation.

Inclusion Criteria:

• Planned HeartMate II LVAD implantation
• Planned warfarin (goal INR, 2.0-3.0) and low-dose aspirin therapy post-LVAD placement

Exclusion Criteria:

• Prior history of mechanical circulatory support;
• Body weight < 110 lbs;
• Pre-existing hemolytic, bleeding, or immunologic disorders prior to LVAD implantation;
• Severe aortic stenosis;
• Renal failure requiring dialysis;
• Hepatic dysfunction resulting in severe coagulopathies;
• Recent serious infection;
• Current need for prolonged ventilatory support;
• Prior organ transplantation;
• Blood transfusion within 14 days of the first planned study blood draw;
• Concomitant immunosuppressant or chemotherapeutic agents;
• Pregnant women;
• Decisionally challenged or prisoners;
• Unwilling to provide written informed consent